1. Home
  2. LXFR vs FULC Comparison

LXFR vs FULC Comparison

Compare LXFR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Luxfer Holdings PLC

LXFR

Luxfer Holdings PLC

HOLD

Current Price

$17.10

Market Cap

460.7M

Sector

Industrials

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.72

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXFR
FULC
Founded
1898
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
460.7M
467.8M
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
LXFR
FULC
Price
$17.10
$3.72
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
389.2K
1.6M
Earning Date
04-28-2026
04-27-2026
Dividend Yield
3.65%
N/A
EPS Growth
N/A
N/A
EPS
0.13
N/A
Revenue
$384,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.01
N/A
P/E Ratio
$131.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.26
$2.83
52 Week High
$19.45
$15.74

Technical Indicators

Market Signals
Indicator
LXFR
FULC
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
LXFR
FULC

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: